50P Efficacy and safety of pemigatinib in Chinese patients with unresectable, advanced/ recurrent or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement that failed to prior systemic therapy

• DOI: 10.1016/j.annonc.2021.08.329
• Publication Date: 2021-09-21T14:40:35Z
• Authors: G-M. Shi; X-Y. Huang; T-F. Wen; T-Q. Song; M. Kuang; H-B. Mou; L-Q. Bao; H-T. Zhao; H. Zhao; X-L. Feng; B. Zhang; T. Peng; Y. Zhang; X. Li; H. Yu; Y. Cao; Y. Luo; Y. Wang; J. Fan; J. Zhou
• Keywords: Intrahepatic Cholangiocarcinoma; Systemic therapy; Expanded access; Rescue therapy